ライフサイエンスコーパス: SCT

1 SCT continues to serve as a platform of "operational cur

2 SCT is not associated with reduced fitness in this longi

3 SCT status also is not an independent risk factor for de

4 those with (5.72%) vs those without (6.01%) SCT (mean HbA1c difference, -0.29%; 95% CI, -0.35% to -0

5 A total of 2233 individuals (239 of 1247 SCT carriers [19.2%] vs 1994 of 14,722 noncarriers [13.5

6 ienced decline in eGFR, and 1322 (154 of 485 SCT carriers [31.8%] vs 1168 of 5947 noncarriers [19.6%]

7 , we prospectively collected plasma from 492 SCT patients with newly diagnosed acute GVHD and randoml

8 ) experienced incident CKD, 1719 (150 of 665 SCT carriers [22.6%] vs 1569 of 8249 noncarriers [19.0%]

9 ncarriers [13.5%]) had CKD, 1298 (140 of 675 SCT carriers [20.7%] vs 1158 of 8481 noncarriers [13.7%]

10 ric patients who were scheduled to undergo a SCT were eligible for the study, with 315 patients compl

11 d spleen size were assessed before and after SCT and compared with hematologic response criteria and

12 underwent (18)F-FDG PET/CT before and after SCT.

13 PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [C

14 at immune suppression with cyclosporin after SCT limits T-helper cell (Th) 1 differentiation and inte

15 The patients died 96 and 129 days after SCT, respectively, one of them after receiving additiona

16 context of intense inflammation early after SCT.

17 e prophylaxis of acute intestinal GvHD after SCT.

18 stitution of antiviral T-cell immunity after SCT.

19 antigens by donor dendritic cells late after SCT that is mandatory for the establishment of effective

20 egy to prevent morbidity and mortality after SCT and has been increasingly studied in the last 15 yea

21 IMN occurs rarely in patients after SCT.

22 D8(+) Tc17 population develops rapidly after SCT but fails to maintain lineage fidelity such that the

23 subjects stabilized for several weeks after SCT, but finally deteriorated.

24 patients (58.1%) were alive at 1 year after SCT and completed additional assessments at 1, 3, and 5

25 cognitive losses during the first year after SCT and to maximize potential recovery.

26 d-effects models with a knot at 1 year after SCT) revealed a significant impact of age and TBI over t

27 sses experienced during the first year after SCT, demonstrating stability in their functioning, but a

28 At 5 years after SCT, the youngest patients (< 3 years old at baseline) w

29 ional assessments at 1, 3, and 5 years after SCT.

30 In B-cell precursor ALL, SCT also benefitted patients with focal IKZF1 gene delet

31 nkfurt-Muenster (BFM) study group trial: ALL-SCT-BFM 2003 (Allogeneic Stem Cell Transplantation in Ch

32 Allo-SCT has a high morbidity and is precluded for many patie

33 allo-SCT led to a significant reduction in the size of the HI

34 chronic HIV infection before and after allo-SCT to measure the size of the HIV-1 reservoir and chara

35 Early after allo-SCT, CD8+ stem cell memory T cells targeting minor histo

36 te significantly to BPDCN control after allo-SCT.

37 therapy for newly diagnosed cGVHD after allo-SCT.

38 in the skin of patients with GVHD after allo-SCT.

39 comparison, being in first remission at allo-SCT favorably influenced survival, whereas age, donor so

40 lude that high-dose therapy followed by allo-SCT from related or unrelated donors can provide durable

41 manipulate the graft content to improve allo-SCT outcome.

42 otherapy to prevent or treat relapse in allo-SCT patients.

43 directly promotes their development in allo-SCT.

44 Nineteen allo-SCT patients (56%) received transplantations in first co

45 (allo-SCT), several subsequent cases of allo-SCT in HIV-1 positive individuals have failed to cure HI

46 lication occurs in approximately 50% of allo-SCT recipients.

47 ional cycles of blinatumomab instead of allo-SCT.

48 A total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the Eur

49 d allogeneic stem cell transplantation (allo-SCT) as consolidation for blinatumomab and 2 who receive

50 ematopoietic stem cell transplantation (allo-SCT) is potentially curative for a number of hematologic

51 t allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT).

52 n allogeneic stem cell transplantation (allo-SCT) patients and their ex vivo generation for additive

53 g allogeneic stem cell transplantation (allo-SCT), several subsequent cases of allo-SCT in HIV-1 posi

54 t allogeneic stem cell transplantation (allo-SCT).

55 r allogeneic stem cell transplantation (allo-SCT).

56 r allogeneic stem cell transplantation (allo-SCT).

57 r allogeneic stem cell transplantation (allo-SCT).

58 ve antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia.

59 Allogeneic SCT in first remission has potent antileukemic efficacy

60 Allogeneic SCT is an established treatment for AML with intermediat

61 Allogeneic SCT led to a significantly prolonged RFS in patients wit

62 Allogeneic SCT may be extended to almost all patients with AML, and

63 A total of 104 patients (84 allogeneic SCT recipients and 20 patients with leukemia) received i

64 oring of treatment response after allogeneic SCT for myelofibrosis.

65 ts whose disease progressed after allogeneic SCT.

66 g the CMV reactivation risk after allogeneic SCT.

67 tet(low) and tet(high) CTLs after allogeneic SCT.

68 nostic factors of survival in all allogeneic SCT recipients admitted to the ICU between 2002 and 2013

69 ients were intended to receive an allogeneic SCT if an HLA-identical sibling donor was available.

70 patients with acute leukemia and allogeneic SCT recipients.

71 om 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT.

72 Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and b

73 patients with an available donor, allogeneic SCT may also be considered.

74 s with NPM1(mut) AML eligible for allogeneic SCT in a donor versus no-donor analysis.

75 l determine the best approach for allogeneic SCT in the future.

76 For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence int

77 ify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy.

78 The outcomes of allogeneic SCT are comparable in patients with therapy-related or d

79 Early mortality of allogeneic SCT recipients admitted to the ICU is especially influen

80 re (p = 0.007) and not undergoing allogeneic SCT (p = 0.007) was found to significantly predict poor

81 counts among patients undergoing allogeneic SCT or chemotherapy and because platelet transfusions ma

82 Of 349 patients who underwent allogeneic SCT during the study period, 92 patients (26%) were admi

83 ent (long-term disease control vs allogeneic SCT).

84 Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvag

85 , the relative risk of death after allogenic SCT vs those treated with nontransplant modalities was 5

86 high-risk PMF clearly benefit from allogenic SCT.

87 ears old at diagnosis who received allogenic SCT (n = 190) or conventional therapies (n = 248).

88 nent strategy composed of STD, ASP, ENV, and SCT was the most effective intervention (rate ratio [RR]

89 ssociated with improved PFS, but not OS, and SCT was not associated with improved OS among patients a

90 bursts of beta activity in both the RTT and SCT.

91 correlation between aqueous flare values and SCT in HCV patients (r = 0.69; P<0.0001) and between fla

92 ived SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39% to 66%) in t

93 transplantation (SCT) in first remission at SCT time.

94 total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the European Group for Bl

95 h autologous stem cell transplantation (auto-SCT) have shown promising results but have never been te

96 r autologous stem cell transplantation (auto-SCT).

97 naplastic large cell lymphoma), upfront auto-SCT was associated with a superior OS (HR, 0.58; P = .00

98 compared with patients treated without auto-SCT.

99 T performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

100 had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions.

101 d 102 underwent FDG PET/CT before autologous SCT.

102 For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patien

103 lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010.

104 ion (SCT) if they had a donor, or autologous SCT if in MMolR and no donor.

105 e donor received consolidation or autologous SCT.

106 erapy but not in those undergoing autologous SCTs.

107 Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic

108 ed more than three treatment regimens before SCT.

109 To evaluate the association between SCT and HbA1c for given levels of fasting or 2-hour gluc

110 sess the strength of the association between SCT and malaria, using current data for both SCT and mal

111 veal a significant difference in RFS between SCT and no-SCT cohorts.

112 In the ALL-BFM-SCT 2003 trial, MRD was assessed in the bone marrow at d

113 SCT and malaria, using current data for both SCT and malaria infections.

114 eralized junctional epidermolysis bullosa by SCT is a last-ditch attempt still lacking proof of effic

115 The HbA1c difference by SCT was greater at higher fasting (P = .02 for interacti

116 omere length heterogeneity was identified by SCT-pqPCR among cells of various human and mouse cell ty

117 a key modulator of cAMP responses induced by SCT stimulation of SCTR.

118 ity/mortality after hematopoietic stem cell (SCT) or solid organ (SOT) transplant.

119 dysregulated in patients undergoing clinical SCT and is present at very high levels in the plasma of

120 In this cohort, SCT strongly associated with risk of progression to ESRD

121 brentuximab vedotin other than consolidative SCT.

122 in sustained remission without consolidative SCT or any new anticancer therapy.

123 lonization methods (DCL), or source control (SCT), simultaneously.

124 creases from 1:13 at CVT level to 1:2 at CVT+SCT level for room temperature.

125 eory with multidimensional tunneling (MS-CVT/SCT) at the high-pressure limit.

126 DI-SCT is a fast and safe tool to identify simulated sleep

127 g drug-induced sleep computed tomography (DI-SCT) in patients with OSA.

128 utations in MYH3 underlie autosomal dominant SCT, identify a postnatal role for embryonic myosin and

129 resetting drift-diffusion model (DDM) during SCT.

130 sequentially and that are resetting in each SCT tap.

131 arge cholangiocytes with knocked down either SCT or SR by short hairpin RNAs show reduced EV secretio

132 However, even following SCT, patients may relapse and die of their disease, unde

133 nt NK cells were licensed in hosts following SCT-K(b) induction, NK cells were not licensed after ind

134 ssion levels of these two proteins following SCT, we showed that in vivo eIF5A1 up-regulation and dow

135 ntional high-risk factor were candidates for SCT in first complete remission.

136 itially normal weight gain, the decision for SCT from haploidentical bone marrow or peripheral blood

137 Intergrader ICCs were greater for SCT (0.959-0.980) than for TCT (0.928-0.963) and VCT (0.

138 Intergrader CRs were lower for SCT (41.40-62.31) than for TCT (61.13-74.24) or VCT (72.

139 ystem to kill CLL cells without the need for SCT.

140 are have improved the risk-benefit ratio for SCT, expanding its indications.

141 nd debilitated patients who may benefit from SCT; the application of SCT has been further increased b

142 uring LPS stimulation, and EVs isolated from SCT or SR knocked down cholangiocytes fail to induce inf

143 The median time from SCT to IMN was 7 months.

144 Furthermore, SCT-pqPCR detected the telomere length for quiescent cel

145 However, SCT calculations show that a narrower barrier and smalle

146 However, SCT was associated with longer RFS in patients with post

147 ed risk for exertion-related sudden death in SCT carriers is unlikely related to fitness.

148 ic lymphocytes (CTLs), although effective in SCT, is less successful after SOT where lifelong immunos

149 tion of the intervals produced by monkeys in SCT is replicated by the model.

150 tion of the intervals produced by monkeys in SCT.

151 racker CM-H2TMRosa, is higher in CTB than in SCT in culture and living explants.

152 glycolysis, are both greater in CTB than in SCT in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x

153 /ms; P<0.0001) and a significantly increased SCT (362.7+/-46.5 mum vs. 320.25+/-32.82 mum; P<0.0001)

154 on, NK cells were not licensed after induced SCT-K(b) expression on NK cells themselves in MHC class

155 urthermore, hematopoietic cells with induced SCT-K(b) licensed NK cells more efficiently than stromal

156 Moreover, differentiation into SCT leads to metabolic suppression.

157 for single-cell telomere length measurement (SCT-pqPCR).

158 Because of migration, SCT is becoming common outside tropical countries: It is

159 Nevertheless, SCT still remains an option for accelerated/blastic-phas

160 ificant difference in RFS between SCT and no-SCT cohorts.

161 ce is associated with an increase by 4.3% of SCT carriers.

162 ge is associated with an increase by 5.5% of SCT carriers.

163 iation of AT1aR with SCTR reduced ability of SCT to stimulate cyclic adenosine monophosphate (cAMP),

164 R of CLARA over HDAC before or in absence of SCT was 0.65 (95% CI, 0.43 to 0.98; P = .041).

165 A1c stratified by the presence or absence of SCT was the primary outcome measure.

166 who may benefit from SCT; the application of SCT has been further increased by reduced-intensity cond

167 We evaluated the association of SCT status with cross-sectional and longitudinal changes

168 nalysis, there was neither an association of SCT status with longitudinal changes in fitness nor an a

169 quations (GEE) to examine the association of SCT with HbA1c levels, controlling for fasting or 2-hour

170 Tolerance induction protocol consisted of SCT/DST under conditioning with bortezomib, methylpredni

171 olicy implications for genetic counseling of SCT carriers.

172 To handle the confounding effect of SCT that could occur in patients with late donor identif

173 tructure of the internally timed elements of SCT.SIGNIFICANCE STATEMENT The present study used behavi

174 ividuals have an autosomal recessive form of SCT and are homozygous or compound heterozygous for nons

175 tologous SCT indicates a lower likelihood of SCT success.

176 Americans in these cohorts, the presence of SCT was associated with an increased risk of CKD, declin

177 Presence of SCT.

178 Overall, the prevalence of SCT was 6.8% (136/1995) in CARDIA, and over the course o

179 past 2 years since the last major review of SCT for PID.

180 We attempt to define the role of SCT in the era of targeted therapies and discuss questio

181 Further investigations into the roles of SCT and novel agents are needed.

182 nalysis, RT or low hemoglobin at the time of SCT predicted shorter OS.

183 dentifies well babies with SCID: the optimal SCT protocol for such young infants remains to be determ

184 When ENV was added to STD+ASP or SCT was added to STD+ENV, there was a significant reduct

185 at low catechol loadings on solid particles (SCT).

186 I and age on cognitive outcomes in pediatric SCT survivors.

187 receiving or were candidates to receive post-SCT cell-based therapies were not included in this analy

188 Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled p

189 rall, 110 patients (55 in each arm) received SCT in first remission.

190 itivity analysis, when patients who received SCT in first remission were censored at SCT time, 2-year

191 on homomers of either receptor, and reduced SCT-stimulated cAMP responses in cells expressing both r

192 ve chart review of the Mayo Clinic Rochester SCT database between January 1997 and August 2012.

193 rican Americans (1248 participants with SCT [SCT carriers] and 14,727 participants without SCT [nonca

194 Angiotensin (ANGII) and secretin (SCT) share overlapping, interdependent osmoregulatory fu

195 gastrointestinal peptide hormone, secretin (SCT) that binds to secretin receptor (SR), is a key medi

196 egardless of the time that had elapsed since SCT.

197 easured to the border of the choroid stroma (SCT) than the vascular lumen (VCT) or sclera (TCT).

198 The syncytiotrophoblast (SCT) at the maternal-fetal interface has been presumed t

199 Spondylocarpotarsal synostosis (SCT) is a skeletal disorder characterized by progressive

200 forming a synchronization-continuation task (SCT) and a serial reaction-time task (RTT), where the an

201 using the synchronization-continuation task (SCT), where subjects initially tap in synchrony with an

202 a synchronization-continuation tapping task (SCT).

203 inically validated standard comparator test (SCT), the GP5+/6+ enzyme immunoassay (EIA).

204 fitness is not known, despite concerns that SCT is associated with exertion-related sudden death.

205 These findings suggest that SCT may be associated with the higher risk of kidney dis

206 in Ph+ ALL adult patients and suggests that SCT in first CR is still a good option for Ph+ ALL adult

207 6 and HPV18/45 between the Xpert HPV and the SCT was also analyzed.

208 lic rate of the placenta is dominated by the SCT contribution.

209 During the SCT, beta was higher during the internally driven contin

210 rebound during the continuation phase of the SCT suggests that the corticostriatal circuit is involve

211 r (CIN2+) and CIN3+ relative to those of the SCT were assessed as were the inter- and intralaboratory

212 nitial burst of beta at the beginning of the SCT, similar to the RTT, followed by a decrease in beta

213 tabolic rate of CTB is much greater than the SCT.

214 g LPS stimulation, and demonstrates that the SCT/SR axis may be important for this event.

215 the undifferentiated CTB, in contrast to the SCT, is highly metabolically active, has a high level of

216 The SCTs bind such that the triazolinone ring is inserted de

217 the thiazolium ring is cleaved, but when the SCTs bind, ThDP is modified to thiamine 2-thiazolone dip

218 Subfoveal choroidal thickness (SCT) was measured using the SDOCT.

219 hickness (VCT), stromal choroidal thickness (SCT), and total choroidal thickness (TCT), respectively.

220 choroid stroma (stromal choroidal thickness, SCT), or inner scleral border (total choroidal thickness

221 y factor significantly interacting with this SCT effect.

222 Exome sequence analysis of three SCT patients negative for FLNB mutations identified an a

223 bolic activity during CTB differentiation to SCT is prevented with a p38 MAPK signaling inhibitor and

224 rsus-host disease and an initial response to SCT predicted longer OS.

225 portant, providing differential signaling to SCT in settings of hyperosmolality or food intake, modul

226 The association between sickle cell trait (SCT) and chronic kidney disease (CKD) is uncertain.

227 lobin variants, including sickle cell trait (SCT) and hemoglobin C trait, have a role in kidney disea

228 differ between those with sickle cell trait (SCT) and those without it.

229 The contribution of sickle cell trait (SCT) to racial disparities in cardiopulmonary fitness is

230 eterozygous state, called sickle cell trait (SCT).

231 14 to 28 days after spinal cord transection (SCT) in rats.

232 induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients with previously unt

233 ceived a consolidative stem cell transplant (SCT) with median PFS not reached.

234 e following autologous stem cell transplant (SCT), multiple treatment options are available, includin

235 undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall survival.

236 ase have expanded stem cell transplantation (SCT) availability for chronic lymphocytic leukemia (CLL)

237 Hematopoietic stem cell transplantation (SCT) can be curative for myeloid malignancies such as ac

238 after allogeneic stem cell transplantation (SCT) for myelofibrosis.

239 Allogeneic stem cell transplantation (SCT) has been proposed as a therapeutic approach, yet wi

240 le for allogeneic stem cell transplantation (SCT) if they had a donor, or autologous SCT if in MMolR

241 after allogeneic stem cell transplantation (SCT) in both mice and humans.

242 ceived allogeneic stem cell transplantation (SCT) in first remission at SCT time.

243 ole of allogeneic stem cell transplantation (SCT) in patients treated in the GRAALL-2003 and GRAALL-2

244 Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patien

245 Allogeneic stem cell transplantation (SCT) is a unique procedure, primarily in patients with h

246 after allogeneic stem cell transplantation (SCT) is hindered by adverse events and drug-drug interac

247 eic hematopoietic stem cell transplantation (SCT) is the only curative option for patients with prima

248 ion of allogeneic stem cell transplantation (SCT) recipients to the intensive care unit (ICU) remains

249 or for allogeneic stem-cell transplantation (SCT) were eligible.

250 lowing allogeneic stem cell transplantation (SCT), the mechanisms of which are unclear.

251 rgoing allogeneic stem cell transplantation (SCT), using the composite end point of graft-versus-host

252 ard to allogeneic stem-cell transplantation (SCT), we compared the clinical course of patients with N

253 after allogeneic stem cell transplantation (SCT).

254 ndergo allogeneic stem cell transplantation (SCT).

255 sed on allogeneic stem cell transplantation (SCT).

256 after allogeneic stem cell transplantation (SCT).

257 neic haemopoietic stem-cell transplantation (SCT).

258 after allogeneic stem cell transplantation (SCT).

259 PID) disorders by stem cell transplantation (SCT); we have focused on articles published in the past

260 receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in those undergoing autolo

261 of the sulfonylamino-carbonyl-triazolinone (SCT) herbicide families, revealing the structural basis

262 multidimensional small-curvature tunneling (SCT) computations indicate that, under cryogenic conditi

263 CVT) inclusive of small curvature tunneling (SCT) reveals the influential role of quantum mechanical

264 Of the 3305 patients who underwent SCT, 12 patients (0.36%) had IMN.

265 showed greater reliability for averaged VCT, SCT, or TCT measurements than at individual locations.

266 CTB than in SCT in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x min(-1) x 100 ng DNA(-1), p < 0

267 DNA(-1), p < 0.001) and (CTB: 43 +/- 6.7 vs SCT 1.4 +/- 1.0 mpH x min(-1) x 100 ng DNA(-1), p < 0.00

268 to obtain direct dynamics multipath (MP-VTST/SCT) gas-phase rate coefficients.

269 ronment, catechol degradation decreased when SCT was <1 mug/mg but increased when SCT was >1 mug/mg.

270 ed when SCT was <1 mug/mg but increased when SCT was >1 mug/mg.

271 ent osmoregulatory functions in brain, where SCT peptide/receptor function is required for ANGII acti

272 00 (Kowa Company Ltd, Tokyo, Japan), whereas SCT was evaluated by using enhanced depth imaging optica

273 valuated 9909 self-reported blacks (739 with SCT and 243 with hemoglobin C trait).

274 ] years; 2835 women [61.3%]; 367 [7.9%] with SCT) with 9062 concurrent measures of fasting glucose an

275 Sex is not associated with SCT.

276 ophasic course and temporal association with SCT and (2) a paraneoplastic phenomenon, supported by fr

277 he plasma of patients with IPS compared with SCT recipients without complications.

278 th individuals without SCT, individuals with SCT had a hazard ratio for ESRD of 2.03 (95% confidence

279 Individuals with SCT had an increased risk of CKD (odds ratio [OR], 1.57

280 ccurred in 40 of 739 (5.4%) individuals with SCT, six of 243 (2.5%) individuals with hemoglobin C tra

281 ed African Americans (1248 participants with SCT [SCT carriers] and 14,727 participants without SCT [

282 per 1000 person-years for participants with SCT and 4.0 per 1000 person-years for noncarriers.

283 s in 572 observations from participants with SCT and 6877 observations from participants without SCT;

284 well-established cohorts, participants with SCT had lower levels of HbA1c at any given concentration

285 participants without SCT, participants with SCT had similar baseline measures of fitness in cross-se

286 significantly lower among participants with SCT when defined using HbA1c values (29.2% vs 48.6% for

287 stimate past glycemia in black patients with SCT and may require further evaluation.

288 DRT with sustained generation of pTregs with SCT.

289 ucose and HbA1c concentration for those with SCT (mean, 5.35%) vs those without SCT (mean, 5.65%) for

290 rance induction protocol (TIP) was used with SCT in group 1, DST in group 2, and no induction in grou

291 ve excellent long-term outcomes even without SCT.

292 Compared with individuals without SCT, individuals with SCT had a hazard ratio for ESRD of

293 CT carriers] and 14,727 participants without SCT [noncarriers]).

294 Participants without SCT data, those without any concurrent HbA1c and glucose

295 Compared with participants without SCT, participants with SCT had similar baseline measures

296 r glucose compared with participants without SCT.

297 6877 observations from participants without SCT; P<.001 for both comparisons).

298 hose with SCT (mean, 5.35%) vs those without SCT (mean, 5.65%) for a mean HbA1c difference of -0.30%

299 e adjusted on the time-dependent treatment x SCT interaction term.

300 of a multivariable Cox-adjusted treatment x SCT interaction, the HR of CLARA over HDAC before or in